Welcome to our dedicated page for Gain Therapeutics news (Ticker: $GANX), a resource for investors and traders seeking the latest updates and insights on Gain Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gain Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gain Therapeutics's position in the market.
Gain Therapeutics has announced that its late-breaking abstract on GT-02287, a clinical-stage GCase enhancer, has been accepted for presentation at the FENS Forum 2024 in Vienna. New data reveals improvements in cognitive performance in a preclinical model of GBA1 Parkinson’s disease. The presentation is scheduled for June 27, 2024, and will be delivered by Dr. Beatriz Calvo-Flores Guzman. The FENS Forum is Europe's largest neuroscience congress, encompassing both basic and translational research. This recognition could potentially highlight the innovative strides Gain Therapeutics is making in the biotechnology sector, particularly in treating neurodegenerative diseases.
Gain Therapeutics (Nasdaq: GANX) has released its Q1 2024 financial results, reporting positive developments despite a decrease in both R&D and G&A expenses. The company announced favorable outcomes from the SAD part of its Phase 1 GT-02287 trial, initiated the MAD portion, and presented promising data on neuroprotection in Parkinson’s models.
Key executive appointments were made, with Gene Mack as CFO and Jonas Hannestad as CMO. The company maintains a cash runway into 2025, supported by potential grant applications. Financially, R&D expenses decreased by $0.3M to $2.5M, and G&A expenses fell by $0.6M to $1.9M. Net loss per share improved to $0.22 from $0.43 YoY. Cash reserves dropped to $12.7M from $16.8M year-end 2023.